News & Publications

SU2C-CRI Cancer Immunology Translational Research Dream Team

Published on Dec 12, 2012

Stand Up To Cancer (SU2C) and the Cancer Research Institute (CRI) announce the formation of a Dream Team project dedicated to cancer immunology — "Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy." Cancer immunology is a field of research that explores the complex relationship between cancer and the immune system, with the goal of discovering immune-based solutions to curing cancer.

The SU2C-CRI Cancer Immunology Translational Research Dream Team will receive $10 million in funding over three years for this translational cancer research project that will unite laboratory and clinical efforts leading to the immunological treatment, control and prevention of cancer.

The team will be led by James P. Allison, Ph.D., and Antoni Ribas, M.D., Ph.D. Allison is chairman of the department of immunology, director of the immunotherapy platform and co-director of the David H. Koch Center for Applied Research of Genitourinary Cancers at The University of Texas MD Anderson Cancer Center. Ribas is professor of medicine, surgery and molecular and medical pharmacology, director of the tumor immunology program area at the Jonsson Comprehensive Cancer Center, and member of the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the University of California, Los Angeles (UCLA).

"The goal of our Dream Team is to expand, optimize and explore combinations of two novel immunotherapies, immune checkpoint blockade and adoptive T-cell transfer," said Allison. "It is our dream, indeed our expectation, that by optimizing these two uniquely successful and complementary approaches, we will be able achieve durable responses in a large percentage of patients suffering from a variety of types of cancer."